The COLON Study: Colorectal Cancer Cohort

Status Recruiting

Clinical Trial Summary

The main aim of this observational, prospective cohort study is to assess associations of diet and other lifestyle factors with colorectal cancer recurrence, survival and quality of life.

Clinical Trial Description

The COLON study is a multi-centre prospective cohort study among incident colorectal cancer patients recruited from 12 hospitals in the Netherlands. Patients with colorectal cancer are invited upon diagnosis. Upon recruitment, after 6 months, 2 years and 5 years, patients fill out food-frequency questionnaires; questionnaires about dietary supplement use, physical activity, weight, height, and quality of life; and donate blood samples. Diagnostic CT-scans are collected to assess cross-sectional areas of skeletal muscle, subcutaneous fat, visceral fat and intermuscular fat, and to assess muscle attenuation. Blood samples are biobanked to facilitate future analyse of biomarkers, nutrients, DNA etc. Analysis of serum 25-hydroxy vitamin D levels, B-vitamins and metabolomic profiles are scheduled. A subgroup of patients with colon cancer is asked to provide faecal samples before and at several time points after colon resection to study changes in gut microbiota during treatment. For all patients, information on vital status is retrieved by linkage with national registries. Information on clinical characteristics, including treatment-related toxicity and co-morbidity data, is gathered from linkage with the Netherlands Cancer Registry and with hospital databases or medical records. Hazard ratios will be calculated for dietary and lifestyle factors at diagnosis in relation to recurrence and survival. Repeated measures analyses will be performed to assess changes over time in dietary and other factors in relation to recurrence and survival.

The aim is to recruit at least 2000 patients with available data and blood samples. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03191110
Study type	Observational
Source	Wageningen University
Contact	Dieuwertje Kok, PhD
Phone	+31 317 485 901
Email	dieuwertje.kok@wur.nl
Status	Recruiting
Phase
Start date	August 3, 2010
Completion date	December 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04712292` - Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Active, not recruiting	`NCT03775980` - CIRSE Emprint Microwave Ablation Registry
Recruiting	`NCT05155124` - Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC	Phase 1
Recruiting	`NCT06050447` - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Active, not recruiting	`NCT03993626` - A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT06314971` - Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Not yet recruiting	`NCT04744688` - Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Recruiting	`NCT06342440` - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting	`NCT05853094` - Postoperative Effects of Different Enterostomy Approaches	N/A
Recruiting	`NCT06200831` - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases	N/A
Recruiting	`NCT02758951` - Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Phase 2/Phase 3
Recruiting	`NCT03686254` - The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM	Phase 2/Phase 3
Recruiting	`NCT05278351` - Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC	Phase 2
Recruiting	`NCT04873895` - TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)	Phase 1
Completed	`NCT04002128` - Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery	N/A
Recruiting	`NCT06208371` - Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM	Phase 3
Not yet recruiting	`NCT06067620` - Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy	N/A
Not yet recruiting	`NCT05129774` - Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM	N/A
Completed	`NCT03507699` - Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer	Phase 1
Active, not recruiting	`NCT03581890` - Socioeconomic Position in Acute Colorectal Cancer Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The COLON Study: Colorectal Cancer Cohort — COLON

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms